A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Eloralintide (Primary) ; Tirzepatide (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 11 Apr 2025 New trial record